

Ali Manouchehrinia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9506768/publications.pdf>

Version: 2024-02-01

56
papers

2,172
citations

236612

25
h-index

243296

44
g-index

57
all docs

57
docs citations

57
times ranked

2631
citing authors

#	ARTICLE	IF	CITATIONS
1	A controlled, randomized phase II clinical trial for efficacy and safety evaluation of mannuronic acid in secondary progressive form of multiple sclerosis. <i>International Journal of Neuroscience</i> , 2022, 132, 403-412.	0.8	2
2	Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse. <i>Annals of Neurology</i> , 2022, 91, 417-423.	2.8	8
3	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. <i>Lancet Neurology</i> , The, 2022, 21, 246-257.	4.9	210
4	Smoking Attributable Risk in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2022, 13, 840158.	2.2	11
5	Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in Sweden. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732210924.	0.5	2
6	P243 Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulating drug levels and early relapse in patients undergoing treatment for systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, .	0.9	2
7	Accurate classification of secondary progression in multiple sclerosis using a decision tree. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1240-1249.	1.4	14
8	Depression and multiple sclerosis: A bidirectional Mendelian randomisation study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1799-1802.	1.4	9
9	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. <i>Frontiers in Neurology</i> , 2021, 12, 647811.	1.1	17
10	Alcohol Consumption and Risk of Common Autoimmune Inflammatory Diseases—Evidence From a Large-Scale Genetic Analysis Totaling 1 Million Individuals. <i>Frontiers in Genetics</i> , 2021, 12, 687745.	1.1	12
11	Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study. <i>Scientific Reports</i> , 2021, 11, 14987.	1.6	13
12	Validating the diagnosis of multiple sclerosis using Swedish administrative data in Värmland County. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 680-686.	1.0	4
13	A multiple sclerosis disease progression measure based on cumulative disability. <i>Multiple Sclerosis Journal</i> , 2021, 27, 135245852098863.	1.4	3
14	Season of birth is associated with multiple sclerosis and disease severity. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110657.	0.5	1
15	Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 139-143.	1.7	126
16	Importance of early treatment decisions on future income of multiple sclerosis patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732095911.	0.5	6
17	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	3.7	32
18	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. <i>Neurology</i> , 2020, 94, e2457-e2467.	1.5	61

#	ARTICLE	IF	CITATIONS
19	Determinants of quality of life in pediatric- and adult-onset multiple sclerosis. <i>Neurology</i> , 2020, 94, e932-e941.	1.5	20
20	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. <i>Neurology</i> , 2020, 94, e1201-e1212.	1.5	88
21	Author response: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study. <i>Neurology</i> , 2020, 95, 1026-1026.	1.5	1
22	Predicting risk of secondary progression in multiple sclerosis: A nomogram. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1102-1112.	1.4	53
23	Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101414.	0.9	16
24	Multiple sclerosis national registry system in Iran: Validity and reliability of a minimum data set. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 158-161.	0.9	19
25	Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 1028.	4.5	68
26	Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment. <i>PLoS ONE</i> , 2019, 14, e0217208.	1.1	10
27	Long-term disability progression of pediatric-onset multiple sclerosis. <i>Neurology</i> , 2019, 92, e2764-e2773.	1.5	69
28	Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades. <i>JAMA Neurology</i> , 2019, 76, 665.	4.5	52
29	Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 761-767.	0.9	23
30	Disability worsening among persons with multiple sclerosis and depression. <i>Neurology</i> , 2019, 93, e2216-e2223.	1.5	63
31	Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study. <i>Journal of Neurology</i> , 2019, 266, 481-486.	1.8	13
32	Effects of cigarette smoke on immunity, neuroinflammation and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2019, 329, 24-34.	1.1	41
33	Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability. <i>Multiple Sclerosis Journal</i> , 2019, 25, 104-112.	1.4	37
34	Smoking Cessation and the Reduction of Disability Progression in Multiple Sclerosis: A Cohort Study. <i>Nicotine and Tobacco Research</i> , 2018, 20, 589-595.	1.4	32
35	Characterization of annual disease progression of multiple sclerosis patients: A population-based study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 786-794.	1.4	10
36	Multiple sclerosis treatment effects on plasma cytokine receptor levels. <i>Clinical Immunology</i> , 2018, 187, 15-25.	1.4	7

#	ARTICLE	IF	CITATIONS
37	Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Multiple Sclerosis Journal, 2018, 24, 1224-1233.	1.4	86
38	Association of Pre-Disease Body Mass Index With Multiple Sclerosis Prognosis. Frontiers in Neurology, 2018, 9, 232.	1.1	31
39	Clinical course of multiple sclerosis: A nationwide cohort study. Multiple Sclerosis Journal, 2017, 23, 1488-1495.	1.4	48
40	Similar familial risk in multiple sclerosis subgroups. Multiple Sclerosis Journal, 2017, 23, 1782-1785.	1.4	3
41	Age Related Multiple Sclerosis Severity Score: Disability ranked by age. Multiple Sclerosis Journal, 2017, 23, 1938-1946.	1.4	107
42	Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. Journal of NeuroVirology, 2017, 23, 839-844.	1.0	17
43	Re: Declines in the diagnosis of primary progressive MSâ€”A critical change in phenotype or critical measurement error?. Multiple Sclerosis Journal, 2017, 23, 305-307.	1.4	0
44	Importance of early treatment initiation in the clinical course of multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1233-1240.	1.4	121
45	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	3.7	94
46	The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis. Frontiers in Neurology, 2017, 8, 675.	1.1	43
47	Income in Multiple Sclerosis Patients with Different Disease Phenotypes. PLoS ONE, 2017, 12, e0169460.	1.1	13
48	A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study. Multiple Sclerosis Journal, 2016, 22, 1071-1079.	1.4	34
49	Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 324-331.	0.9	95
50	Multiple sclerosis course and clinical outcomes in patients with comorbid asthma: a survey study. BMJ Open, 2015, 5, e007806-e007806.	0.8	10
51	Effect of Smoking Cessation on Multiple Sclerosis Prognosis. JAMA Neurology, 2015, 72, 1117.	4.5	124
52	Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1091-1095.	0.9	41
53	Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain, 2013, 136, 2298-2304.	3.7	127
54	Association of Multiple sclerosis with Other Autoimmune Diseases. , 2013, , 341-356.		0

#	ARTICLE	IF	CITATIONS
55	Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 592-600.	2.0	19
56	Reduced EDSS progression in multiple sclerosis patients treated with modafinil for three years or more compared to matched untreated subjects. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 131-135.	0.9	4